Mechanistic Studies and Their Implication for the Management of Fibromyalgia Syndrome

REFERENCES

• Wolfe F, Smythe H A, Yunus M B, Bennett R M, Bombardier C, Goldenberg D L, Tugwell P, Campbell S M, Abeles M, Clark P, Fam A G, Farber S J, Fiechtner J J, Franklin C M, Gatter R A, Hamaty D, Lessard J, Lichtbroun A S, Masi A T, McCain G A, Reynolds W J, Romano T J, Russell I J, Sheon R P. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Arthritis Rheum, 33: 160–172
   PubMed Web of Science ®Google Scholar
• Arnold L M, Hudson J I, Hess E V, Ware A E, Fritz D A, Auchenbach M B, Starck L O, Keck P E, Jr. Family study of fibromyalgia. Arthritis Rheum 2004; 50(3)944–952
   PubMed Web of Science ®Google Scholar
• Bondy B, Spaeth M, Offenbaecher M, Glatzeder K, Stratz T, Schwarz M, de Jonge S, Kruger M, Engel R R, Farber L, Pongratz D E, Ackenheil M. The T102C polymorphism of the 5-HT2A-receptor gene in fibromyalgia. Neurobiol Dis 1999; 6(5)433–439
   PubMedGoogle Scholar
• Offenbaecher M, Bondy B, de Jonge S, Glatzeder K, Kruger M, Schoeps P, Ackenheil M. Possible association of fibromyalgia with a polymorphism in the serotonin transporter gene regulatory region. Arthritis & Rheumatism 1999; 42(11)2482–2488
   PubMedGoogle Scholar
• Buskila D, Cohen H, Neumann L, Ebstein R P. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004; 9(8)730–731
   PubMedGoogle Scholar
• Clauw D J, Chrousos G P. Chronic pain and fatigue syndromes: Overlapping clinical and neuroendocrine features and potential pathogenic mechanisms. Neuroimmunomodulation 1997; 4(3)134–153
   PubMed Web of Science ®Google Scholar
• Crofford L J, Pillemer S R, Kalogeras K T, Cash J M, Michelson D, Kling M A, Sternberg E M, Gold P W, Chrousos G P, Wilder R L. Hypothalamic-pituitary-adrenal axis perturbations in patients with fibromyalgia. Arthritis & Rheumatism 1994; 37(11)1583–1592
   PubMed Web of Science ®Google Scholar
• Demitrack M A, Crofford L J. Evidence for and pathophysiologic implications of hypothalamic-pituitary-adrenal axis dysregulation in fibromyalgia and chronic fatigue syndrome. Ann N Y Acad Sci, 840: 684–697
   PubMedGoogle Scholar
• Qiao Z G, Vaeroy H, Morkrid L. Electrodermal and microcirculatory activity in patients with fibromyalgia during baseline, acoustic stimulation and cold pressor tests. Journal of Rheumatology 1991; 18(9)1383–1389
   PubMedGoogle Scholar
• Adler G K, Kinsley B T, Hurwitz S, Mossey C J, Goldenberg D L. Reduced hypothalamic-pituitary and sympathoadrenal responses to hypoglycemia in women with fibromyalgia syndrome. American Journal of Medicine 1999; 106(5)534–543
   PubMed Web of Science ®Google Scholar
• Martinez-Lavin M, Hermosillo A G, Rosas M, Soto M E. Circadian studies of autonomic nervous balance in patients with fibromyalgia: A heart rate variability analysis. Arthritis & Rheumatism 1998; 41(11)1966–1971
   PubMed Web of Science ®Google Scholar
• McBeth J, Silman A J, Gupta A, Chiu Y H, Ray D, Morriss R, Dickens C, King Y, Macfarlane G J. Moderation of psychosocial risk factors through dysfunction of the hypothalamic-pituitary-adrenal stress axis in the onset of chronic widespread musculoskeletal pain: Findings of a population-based prospective cohort study. Arthritis Rheum 2007; 56(1)360–371
   PubMed Web of Science ®Google Scholar
• Glass J M, Lyden A K, Petzke F, Stein P, Whalen G, Ambrose K, Chrousos G, Clauw D J. The effect of brief exercise cessation on pain, fatigue, and mood symptom development in healthy, fit individuals. J Psychosom Res 2004; 57(4)391–398
   PubMed Web of Science ®Google Scholar
• Lautenbacher S, Rollman G B, McCain G A. Multi-method assessment of experimental and clinical pain in patients with fibromyalgia. Pain 1994; 59(1)45–53
   PubMed Web of Science ®Google Scholar
• Gracely R H, Petzke F, Wolf J M, Clauw D J. Functional magnetic resonance imaging evidence of augmented pain processing in fibromyalgia. Arthritis Rheum 2002; 46(5)1333–1343
   PubMed Web of Science ®Google Scholar
• Gracely R H, Geisser M E, Giesecke T, Grant M A, Petzke F, Williams D A, Clauw D J. Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain 2004; 127: 835–843, (Pt 4)
   PubMed Web of Science ®Google Scholar
• Giesecke T, Gracely R H, Grant M A, Nachemson A, Petzke F, Williams D A, Clauw D J. Evidence of augmented central pain processing in idiopathic chronic low back pain. Arthritis Rheum 2004; 50(2)613–623
   PubMed Web of Science ®Google Scholar
• Cook D B, Lange G, Ciccone D S, Liu W C, Steffener J, Natelson B H. Functional imaging of pain in patients with primary fibromyalgia. J Rheumatol 2004; 31(2)364–378
   PubMed Web of Science ®Google Scholar
• Russell I J, Orr M D, Littman B, Vipraio G A, Alboukrek D, Michalek J E, Lopez Y, MacKillip F. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome. Arthritis & Rheumatism 1994; 37(11)1593–1601
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Alberti A, Floridi A, Gallai V. Levels of nerve growth factor in cerebrospinal fluid of chronic daily headache patients. Neurology 2001; 57(1)132–134
   PubMed Web of Science ®Google Scholar
• Alpar E K, Onuoha G, Killampalli V V, Waters R. Management of chronic pain in whiplash injury. J Bone Joint Surg Br 2002; 84(6)807–811
   PubMedGoogle Scholar
• Kosek E, Ekholm J, Hansson P. Sensory dysfunction in fibromyalgia patients with implications for pathogenic mechanisms. Pain 1996; 68(2–3)375–383
   PubMed Web of Science ®Google Scholar
• Julien N, Goffaux P, Arsenault P, Marchand S. Widespread pain in fibromyalgia is related to a deficit of endogenous pain inhibition. Pain 2005; 114(1–2)295–302
   PubMed Web of Science ®Google Scholar
• Baraniuk J N, Whalen G, Cunningham J, Clauw D J. Cerebrospinal fluid levels of opioid peptides in fibromyalgia and chronic low back pain. BMC Musculoskelet Disord 2004; 5(1)48
   PubMedGoogle Scholar
• Russell I J, Vaeroy H, Javors M, Nyberg F. Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis & Rheumatism 1992; 35(5)550–556
   PubMed Web of Science ®Google Scholar
• Yunus M B, Dailey J W, Aldag J C, Masi A T, Jobe P C. Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. Journal of Rheumatology 1992; 19(1)90–94
   PubMedGoogle Scholar
• Hadler N M. If you have to prove you are ill, you can't get well. The object lesson of fibromyalgia. Spine 1996; 21(20)2397–2400
   PubMed Web of Science ®Google Scholar
• Hawley D J, Wolfe F. Pain, disability, and pain/disability relationships in seven rheumatic disorders: A study of 1,522 patients. J Rheumatol 1991; 18(10)1552–1557
   PubMed Web of Science ®Google Scholar
• Callahan L F, Smith W J, Pincus T. Self-report questionnaires in five rheumatic diseases: comparisons of health status constructs and associations with formal education level. Arthritis Care Res 1989; 2(4)122–131
   PubMedGoogle Scholar
• Giesecke T, Gracely R H, Williams D A, Geisser M, Petzke F, Clauw D J. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis & Rheumatism 2005; 52(5)1577–1584
   PubMed Web of Science ®Google Scholar
• Goldenberg D L, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292(19)2388–2395, (2004)
   PubMed Web of Science ®Google Scholar
• White K P, Nielson W R, Harth M, Ostbye T, Speechley M. Does the label “fibromyalgia” alter health status, function, and health service utilization? A prospective, within-group comparison in a community cohort of adults with chronic widespread pain. Arthritis Rheum 2002; 47(3)260–265, (2002)
   PubMed Web of Science ®Google Scholar
• Arnold L M, Keck P EJ, Welge J A. Antidepressant treatment of fibromyalgia. A meta-analysis and review. Psychosomatics 2000; 41(2)104–113
   PubMed Web of Science ®Google Scholar
• Capaci K, Hepguler S. Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome. The Pain Clinic 2002; 14(3)223–228
   Web of Science ®Google Scholar
• Anderberg U M, Marteinsdottir I, Von Knorring L. Citalopram in patients with fibromyalgia—a randomized, double-blind, placebo-controlled study. European Journal of Pain 2000; 4(1)27–35
   PubMed Web of Science ®Google Scholar
• Norregaard J, Volkmann H, Danneskiold-Samsoe B. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61(3)445–449
   PubMed Web of Science ®Google Scholar
• Fishbain D. Evidence-based data on pain relief with antidepressants. Ann Med 2000; 32(5)305–316
   PubMed Web of Science ®Google Scholar
• Adelman L C, Adelman J U, Von Seggern R, Mannix L K. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: A retrospective study in a clinical setting. Headache, 40(7)572–580
   PubMedGoogle Scholar
• Gendreau R M, Thorn M D, Gendreau J F, Kranzler J D, Riberio S, Gracely R H, Williams D A, Mease P J, McLean S A, Clauw D J. The efficacy of Milnacipran in Fibromyalgia. The Journal of Rheumatology 2005; 32(10)1975–1985
   PubMed Web of Science ®Google Scholar
• Arnold L M, Lu Y, Crofford L J, Wohlreich M, Detke M J, Iyengar S, Goldstein D J. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2002; 50(9)2974–2984
   Google Scholar
• Wiffen P, Collins S, McQuay H, Carroll D, Jadad A, Moore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev (3) 2000, CD001133
   Google Scholar
• Fehrenbacher J C, Taylor C P, Vasko M R. Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 2003; 105(1–2)133–141
   PubMedGoogle Scholar
• Maneuf Y P, McKnight A T. Block by gabapentin of the facilitation of glutamate release from rat trigeminal nucleus following activation of protein kinase C or adenylyl cyclase. Br J Pharmacol 2001; 134(2)237–240
   PubMed Web of Science ®Google Scholar
• Maneuf Y P, Hughes J, McKnight A T. Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices. Pain 2001; 93(2)191–196
   PubMed Web of Science ®Google Scholar
• Crofford L J, Rowbotham M C, Mease P J, Russell I J, Dworkin R H, Corbin A E, Young J P, Jr, La Moreaux L K, Martin S A, Sharma U. Pregabalin 1008–105 Study Group: Pregabalin for the treatment of fibromyalgia syndrome: Results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52(4)1264–1273
   PubMed Web of Science ®Google Scholar
• Arnold L M, Goldenberg D L, Stanford S B, Lalonde J K, Sandhu H S, Keck P E, Jr, Welge J A, Bishop F, Stanford K E, Hess E V, Hudson J I. Gabapentin in the treatment of fibromyalgia: A randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007; 56(4)1336–1344
   PubMed Web of Science ®Google Scholar
• Wood P B, Schweinhardt P, Jaeger E, Dagher A, Hakyemez H, Rabiner E A, Bushnell M C, Chizh B A. Fibromyalgia patients show an abnormal dopamine response to pain. Eur J Neurosci 2007; 25(12)3576–3582
   PubMed Web of Science ®Google Scholar
• Holman A J, Myers R R. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005; 52(8)2495–2505
   PubMed Web of Science ®Google Scholar
• Scharf M B, Baumann M, Berkowitz D V. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003; 30(5)1070–1074
   PubMed Web of Science ®Google Scholar
• Moldofsky H. Sleep and musculoskeletal pain. Am J Med 1986; 81(3A)85–89
   PubMedGoogle Scholar
• Russell I J, et al. Therapy with a central alpha 2-adrenergic agonist (tizanidine) decreases cerebrospinal fluid substance P, and may reduce serum hyaluronic acid as it improves the clinical symptoms of the fibromyalgia syndrome. Arthritis & Rheumatism 2002; 46(9)S614
   PubMedGoogle Scholar
• Bennett R M, Kamin M, Karim R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: A double-blind, randomized, placebo-controlled study. Am J Med 2003; 114(7)537–545
   PubMed Web of Science ®Google Scholar
• Bennett R M. Pharmacological treatment of fibromyalgia. J Funct Syndromes 2001; 1(1)79–92
   Google Scholar
• Williams D A, Cary M A, Glazer L J, Rodriguez A M, Clauw D J. Randomized controlled trial of CBT to improve functional status in fibromyalgia. American College of Rheumatology 2000; 43(9)S210
   Google Scholar